好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cancer informatics survey of different grades and subtypes of glioma
Neuro-oncology
P14 - Poster Session 14 (11:45 AM-12:45 PM)
4-003
This work aims to investigate the molecular trajectories of different grades of glioma to see how similar they are using a cancer informatics framework. We hypothesize that such a data-driven approach may aid in the discovery of new drug targets and miRNA that can potentially regulate tumor formation, which may benefit treatment and prognosis studies.
Gliomas are brain tumors that originate in the glial cells. "Glioma" is a blanket term used for defining various kinds of glial tumors, including astrocytoma, oligodendroglioma, and glioblastoma. The aggressiveness or malignancy of gliomas varies. While some are slow-growing and potentially treatable, others are invasive, proliferative, and tend to recur.
We have used a translational bioinformatics approach to proceed with the investigation. We used the Disgenet database to retrieve canonical disease gene sets (18 diseases), including three WHO (World Health Organization) grade-wise tumors and eight WHO grade-wise subtypes of Diffuse astrocytic and oligodendroglia tumors, five other astrocytic tumors, and two high and low-grade tumor datasets.
 Enrichr-based pathway enrichment analysis revealed Viral myocarditis, Hepatitis B and C, Malaria, Measles, Influenza, Tuberculosis, and Alcoholism were enriched across different sub-types. STRING-db was used to compute protein networks using graph-based metrics, and critical genes such as LRRC59, CCDC67, TRMT11, and TMEM135 were identified in Glioblastoma multiforme, while Cytoscape was used to prioritize candidates. cBioPortal was used to analyse datasets in order to find racial, gender and age disparities in CNS tumors.
Further evaluation of these targets could lead to identifying shared and distinct pathways associated with gliomas that could be targeted to develop new treatment approaches. 
Authors/Disclosures
Parampreet Kaur, MS (RAMAIAH UNIVERSITY OF APPLIED SCIENCES)
PRESENTER
Ms. Kaur has nothing to disclose.